Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.
REPORT DATE
01-05-20072. REPORT TYPE
Final
DATES COVERED
PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBERThe University of Texas Southwestern Medical Center at Dallas Dallas, TX 75390-9105
SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S)
U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012
SPONSOR/MONITOR'S REPORT NUMBER(S)
DISTRIBUTION / AVAILABILITY STATEMENTApproved for Public Release; Distribution Unlimited
SUPPLEMENTARY NOTESOriginal contains colored plates: ALL DTIC reproductions will be in black and white.
ABSTRACTThe goal of our project is to image the processes that occur during tumor growth and metastatic spread or regression including the fate of minimal residual disease. To do so it is necessary to test the limits of sensitivity of newly developed techniques: our technical goal is to develop integrated light emission and single photon emission tomography. We have made substantial progress in our techniques for the detection of metastases. We have demonstrated our capability to detect millimeter or sub-millimeter metastases in mice by light emission. To this end we have used Light Emission Tomography (LET), a technique based on bioluminescence of cancer cells infected with luciferase, to detect metastases in the lung and head. We have begun assessment of perfusion using fluorescence imaging. In addition, our technological focus is on the simultaneous use of Single-photon Emission Computed Tomography (SPECT), and to this end we have developed a new form of micro-SPECT based on cooled, electron-multiplied Charge-Coupled Devices (EMCCDs) with which we are performing ongoing imaging experiments. We have also collaborated on the assessment of a new, promising SPECT imaging agent, clioquinol or Iodinated hydroxyquinoline. We will use bioluminescence imaging to test if clioquinol imaging detects areas where tumor cells proliferate and establish metastases and to identify the relative times at which the images first appear.
SUBJECT TERMS
INTRODUCTIONBecause growth of very small tumors has not been s...